AgeneBio Announces Completion of Patient Enrollment in Phase 2B Clinical Trial to Evaluate AGB101 to Treat Amnestic Mild Cognitive Impairment Due to Alzheimer s Disease
- Topline results expected in November 2022
News provided by
Share this article
Share this article
BALTIMORE, April 21, 2021 /PRNewswire/ AgeneBio announced today that it has completed enrollment in a Phase 2B clinical trial evaluating the efficacy of AGB101, a once-a-day investigational medication to treat amnestic Mild Cognitive Impairment due to Alzheimer s Disease (MCI due to AD). The clinical trial, known as HOPE4MCI (NCT03486938), is a 78-week study, randomized, double-blind, placebo controlled study that has enrolled 164 patients across 23 sites in the United States and Canada.